MARKET

XOMA

XOMA

XOMA Royalty Corporation
NASDAQ
41.89
+0.35
+0.83%
Opening 14:36 05/20 EDT
OPEN
41.62
PREV CLOSE
41.54
HIGH
41.98
LOW
41.58
VOLUME
75.15K
TURNOVER
--
52 WEEK HIGH
42.81
52 WEEK LOW
22.29
MARKET CAP
525.28M
P/E (TTM)
25.37
1D
5D
1M
3M
1Y
5Y
1D
Can XOMA's Late-Stage Pipeline Finally Justify the Royalty Model?
Barchart · 2d ago
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals
TipRanks · 2d ago
XOMA Royalty amends Ligand merger deal to add HoldCo as party
PUBT · 2d ago
Weekly Report: what happened at XOMA last week (0511-0515)?
Weekly Report · 2d ago
XOMA Q1 net income falls to $4.5 million; total income and revenues slip to $12.32 million
PUBT · 05/12 20:16
XOMA's Liquidation Pivot May Be Masking a Drying Royalty Stream
Barchart · 05/11 16:09
Weekly Report: what happened at XOMA last week (0504-0508)?
Weekly Report · 05/11 09:41
Weekly Report: what happened at XOMA last week (0427-0501)?
Weekly Report · 05/04 09:41
More
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Webull offers XOMA Royalty Corp stock information, including NASDAQ: XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.